Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer (PRADO)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Redas Trepiakas, MD
- Phone Number: +45 56 51 3231
- Email: rtr@regionsjaelland.dk
Study Contact Backup
- Name: K F E
- Phone Number: + 45 56 51 31 17
- Email: laml@regionsjaelland.dk
Study Locations
-
-
Sjaelland
-
Næstved, Sjaelland, Denmark, DK-4700
- Recruiting
- Dep. Radiation Oncology, Zealand University Hospital
-
Contact:
- K F E
- Phone Number: + 45 56 51 31 17
- Email: laml@regionsjaelland.dk
-
Contact:
- Redas Trepiakas
- Phone Number: +4556513231 +4556513231
- Email: rtr@regionsjaelland.dk
-
-
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
- Not yet recruiting
- University Hospital Schleswig-Holstein
-
Contact:
- Juergen Dunst, MD
- Phone Number: 0049 431 500-26500
- Email: juergen.dunst@uksh.de
-
Lubeck, Schleswig-Holstein, Germany, 23538
- Not yet recruiting
- University Hospital Schleswig-Holstein
-
Contact:
- Dirk Rades, MD
- Phone Number: 0049 451-500-45400
- Email: dirk.rades@uksh.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with hormone refractory biopsy proven prostate cancer
- Presenting with a dominating debilitating symptom
- Expected median survival of 12 months
- Focal irradiation of lesion is feasible
- Systemic therapy according to guidelines
- age ≥18 years
- Legal capacity, able to understand consequences of the trial
- Written informed consent
Exclusion Criteria:
- Relevant comorbidity (limiting radiotherapy according to protocol)
- Prior radiotherapy limitations to administer radiotherapy according to protocol
- No large metal implants in vicinity of lesion
- Department dose constraints for normal tissue can't be met
- Large bony lesions with extensive osseous destruction
- Patients symptoms do not correlate with MR findings
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: feasibilty
Palliative Radiotherapy
|
Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of study participants that complete the study
Time Frame: 6 months
|
Proportion of study participants that complete radiotherapy with ≥ 90% of prescribed dose
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response in dominating symptom score (short form McGill pain Questionnaire)
Time Frame: Baseline, 1,3 and 6 months after radiotherapy
|
Patient score symptom/pain using the short form McGill pain Questionnaire version 2
|
Baseline, 1,3 and 6 months after radiotherapy
|
|
Acute radiation toxicity score using CTCAE
Time Frame: Baseline, 1,3 and 6 months after radiotherapy
|
Doctor score acute radiation toxicity using the CTCAE version 4
|
Baseline, 1,3 and 6 months after radiotherapy
|
|
Quality of life score using EORTC QLQ-C30
Time Frame: Baseline and 6 months after radiotherapy
|
Patient fill out EORTC quality of life Questionnaire form C30
|
Baseline and 6 months after radiotherapy
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Jesper H Carl, Phd, Oncology, Zealand University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PRADO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.